Mahsa Salsabili, PharmD, PhD, underscores the potential cost-effectiveness of treatment through the adoption of prescription digital therapeutics, while acknowledging that additional evidence is required to conclusively determine their cost-effectiveness.
FDA Expands Akili's EndeavorRx Game-Based Digital Therapy for ADHD Eligibility to Ages 8-17
December 21st 2023As the only FDA-approved, game-based digital therapeutic, EndeavorRx’s eligibility is expected to more than double the number of pediatric patients with ADHD who have a prescription from a healthcare provider, due to the increased age range.
Read More